180 related articles for article (PubMed ID: 31921171)
1. Increasing Time in Therapeutic Range of Tacrolimus in the First Year Predicts Better Outcomes in Living-Donor Kidney Transplantation.
Song T; Yin S; Jiang Y; Huang Z; Liu J; Wang Z; Li L; Zeng J; Fan Y; Wang X; Li X; Lin T
Front Immunol; 2019; 10():2912. PubMed ID: 31921171
[No Abstract] [Full Text] [Related]
2. Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor-Specific Antibodies.
Davis S; Gralla J; Klem P; Stites E; Wiseman A; Cooper JE
Transplantation; 2020 Apr; 104(4):881-887. PubMed ID: 32224815
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus Trough Level at the First Month May Predict Renal Transplantation Outcomes Among Living Chinese Kidney Transplant Patients: A Propensity Score-Matched Analysis.
Yin S; Song T; Jiang Y; Li X; Fan Y; Lin T
Ther Drug Monit; 2019 Jun; 41(3):308-316. PubMed ID: 31083041
[TBL] [Abstract][Full Text] [Related]
4. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime.
Whalen HR; Glen JA; Harkins V; Stevens KK; Jardine AG; Geddes CC; Clancy MJ
Transplantation; 2017 Feb; 101(2):430-436. PubMed ID: 26950724
[TBL] [Abstract][Full Text] [Related]
5. Defining a threshold for tacrolimus intra-patient variability associated with late acute cellular rejection in paediatric kidney transplant recipients.
Abu Bakar K; Mohamad NA; Hodi Z; McCulloch T; Williams A; Christian M; Key T; Kim JJ
Pediatr Nephrol; 2019 Dec; 34(12):2557-2562. PubMed ID: 31520127
[TBL] [Abstract][Full Text] [Related]
6. Early Monitoring and Subsequent Gain of Tacrolimus Time-In-Therapeutic Range May Improve Clinical Outcomes After Living Kidney Transplantation.
Yin S; Huang Z; Wang Z; Fan Y; Wang X; Song T; Lin T
Ther Drug Monit; 2021 Dec; 43(6):728-735. PubMed ID: 34780391
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation.
O'Regan JA; Canney M; Connaughton DM; O'Kelly P; Williams Y; Collier G; deFreitas DG; O'Seaghdha CM; Conlon PJ
J Nephrol; 2016 Apr; 29(2):269-276. PubMed ID: 26374111
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus time in therapeutic range and long-term outcomes in heart transplant recipients.
Adie SK; Bitar A; Konerman MC; Dorsch MP; Andrews CA; Pogue K; Park JM
Pharmacotherapy; 2022 Feb; 42(2):106-111. PubMed ID: 34882822
[TBL] [Abstract][Full Text] [Related]
9. Lower tacrolimus time in therapeutic range is associated with inferior outcomes in adult liver transplant recipients.
Song W; Lao Q; Hu J; Li D; Du Y; Zhu H
Basic Clin Pharmacol Toxicol; 2023 Jan; 132(1):51-59. PubMed ID: 36197905
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era.
Gralla J; Wiseman AC
Transplantation; 2009 Jun; 87(11):1712-9. PubMed ID: 19502965
[TBL] [Abstract][Full Text] [Related]
11. Etiologies and Outcomes Associated With Tacrolimus Levels Out of a Typical Range That Lead to High Variability in Kidney Transplant Recipients.
Taber DJ; Hirsch J; Keys A; Su Z; McGillicuddy JW
Ther Drug Monit; 2021 Jun; 43(3):401-407. PubMed ID: 33560095
[TBL] [Abstract][Full Text] [Related]
12. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure.
Sapir-Pichhadze R; Wang Y; Famure O; Li Y; Kim SJ
Kidney Int; 2014 Jun; 85(6):1404-11. PubMed ID: 24336032
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
Refaie AF; Mahmoud KM; Ismail AM; Sheashaa HA; Kamal AI; Ghoneim MA
Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
[TBL] [Abstract][Full Text] [Related]
14. Lower Time in Therapeutic Range Relates to a Worse Kidney Graft Outcome.
Barreda P; Cañamero L; Boya M; García-Saiz MDM; Valero R; Belmar L; Kislikova M; De Cos MA; Ruiz JC; Rodrigo E
Transplant Proc; 2022 Nov; 54(9):2446-2449. PubMed ID: 36272833
[TBL] [Abstract][Full Text] [Related]
15. High tacrolimus intra-patient variability is associated with graft rejection, and
Del Bello A; Congy-Jolivet N; Danjoux M; Muscari F; Lavayssière L; Esposito L; Hebral AL; Bellière J; Kamar N
World J Gastroenterol; 2018 Apr; 24(16):1795-1802. PubMed ID: 29713132
[TBL] [Abstract][Full Text] [Related]
16. Association of the combination of time-weighted variability of tacrolimus blood level and exposure to low drug levels with graft survival after kidney transplantation.
Rozen-Zvi B; Schneider S; Lichtenberg S; Green H; Cohen O; Gafter U; Chagnac A; Mor E; Rahamimov R
Nephrol Dial Transplant; 2017 Feb; 32(2):393-399. PubMed ID: 28025383
[TBL] [Abstract][Full Text] [Related]
17. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
18. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children.
Pollock-Barziv SM; Finkelstein Y; Manlhiot C; Dipchand AI; Hebert D; Ng VL; Solomon M; McCrindle BW; Grant D
Pediatr Transplant; 2010 Dec; 14(8):968-75. PubMed ID: 21040278
[TBL] [Abstract][Full Text] [Related]
19. Deoxyspergualin prophylaxis with tacrolimus further improves long-term graft survival in living-related renal-transplant recipients transfused with donor-specific blood.
Amada N; Okazaki H; Sato T; Ohashi Y; Kikuchi H
Transplant Proc; 2005 Mar; 37(2):927-9. PubMed ID: 15848577
[TBL] [Abstract][Full Text] [Related]
20. Ten-year observational follow-up of a randomized trial comparing cyclosporine and tacrolimus therapy combined with steroid withdrawal in living-donor renal transplantation.
Kim J; Park J; Hwang S; Yoo H; Kim K; Park JB; Jang HR; Lee JE; Kim SJ; Kim YG; Kim DJ; Oh HY; Huh W
Clin Transplant; 2018 Sep; 32(9):e13372. PubMed ID: 30080284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]